Revenue
2018
2019
2020
2021
2022
2023
2024
2025
QUEST DIAGNOSTICS INC (DGX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | $7.15B | $7.38B | $7.39B | $7.26B | $7.46B | $7.25B | $6.70B |
| Gross profit | — | — | — | — | — | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | $2.82B | $3.02B | $3.03B | $3.05B | $3.13B | — | — |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983.0M | $1.48B | $1.20B | $987.0M | $1.28B | $1.36B | $1.22B | $1.09B |
| EBITDAderived | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B | $1.76B | $1.49B | $1.27B | $1.54B | $1.62B | $1.49B | $1.33B |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B | $1.43B | $858.0M | $736.0M | $772.0M | $645.0M | $709.0M | $556.0M | $849.0M | $556.0M | $471.0M | $720.9M | $729.1M | $581.5M | $339.9M |
| Basic EPSper diluted share | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | $5.58 | $3.49 | $2.95 | $4.08 | $3.91 | $2.99 | $1.76 |
| Diluted EPSper diluted share | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | $5.54 | $3.46 | $2.92 | $4.05 | $3.87 | $2.96 | $1.74 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 4, 2026Form 4 · 10b5-1 | KUPPUSAMY KARTHIKSVP, Clinical Solutions | SellCommon Stock | 8.1K | $200.00 | $1.63M | 13.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Davis J. E.CEO and President | SellCommon Stock | 10.0K | $194.14 | $1.94M | 132.4K |
| Mar 5, 2026Form 4 · 10b5-1 | Doherty Catherine T.EVP, Regional Businesses | SellCommon Stock | 5.6K | $206.21 | $1.15M | 67.1K |
| Mar 5, 2026Form 4 · 10b5-1 | PREVOZNIK MICHAEL ESVP & General Counsel | SellCommon Stock | 3.9K | $206.21 | $799.7K | 37.6K |
| Mar 5, 2026Form 4 · 10b5-1 | Plewman PatrickSVP for Diagnostic Services | SellCommon Stock | 2.9K | $206.21 | $588.7K | 15.2K |